Skip to main content
Top
Published in: Thrombosis Journal 1/2023

Open Access 01-12-2023 | Cerebral Sinus Venous Thrombosis | Case Report

Cerebral venous sinus thrombosis associated with SRA-negative heparin-induced thrombocytopenia: case report

Authors: Floyd D. Silva, Allison E. Burnett, Anand Padmanabhan, Marian A. Rollins-Raval, Noah P. Splinter, Masoom J. Desai

Published in: Thrombosis Journal | Issue 1/2023

Login to get access

Abstract

Background

There are very few documented reports in literature of cerebral venous sinus thrombosis (CVST) caused by immune-mediated heparin-induced thrombocytopenia (HIT). Further, there are very few reports of false negative serotonin release assays (SRAs) when testing for immune-mediated HIT.

Case presentation

We present a case of a 60- year-old male with recent unfractionated heparin administration for venous thromboembolism prophylaxis, an elevated 4T score of 5 and acute CVST in which immune-mediated HIT was suspected. The enzyme-linked immunosorbent assay (ELISA) screening assay was positive for PF4 antibodies and subsequent reflexive SRA testing was negative. However, given the clinical picture, a false-negative SRA was suspected (and eventually confirmed), prompting use of the alternative PF4-dependent p-selectin expression assay (PEA) which was confirmed to be positive. The patient was successfully managed with a bivalirudin infusion and eventually transitioned to apixaban.

Conclusion

It is uncommon for immune-mediated HIT with thrombosis to manifest as CVST. Similarly, false-negative SRA is uncommon in immune-mediated HIT. Take-away lessons from our case report include considering HIT in CVST patients with an elevated 4T score and considering the entire clinical picture and degree of suspicion for HIT when interpreting negative HIT testing results. The PEA, in conjunction with the 4Ts score, may be considered as an alternate diagnostic assay for HIT.
Literature
1.
go back to reference Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vasc Med. 2020;25(2):160–73.CrossRefPubMed Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vasc Med. 2020;25(2):160–73.CrossRefPubMed
2.
go back to reference Arepally GM, Padmanabhan A. Heparin-Induced Thrombocytopenia: a focus on thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(1):141–52.PubMed Arepally GM, Padmanabhan A. Heparin-Induced Thrombocytopenia: a focus on thrombosis. Arterioscler Thromb Vasc Biol. 2021;41(1):141–52.PubMed
3.
go back to reference Aguiar de Sousa D, et al. Cerebral venous thrombosis in patients with Heparin-Induced Thrombocytopenia a systematic review. Stroke. 2022;53(6):1892–903.CrossRefPubMed Aguiar de Sousa D, et al. Cerebral venous thrombosis in patients with Heparin-Induced Thrombocytopenia a systematic review. Stroke. 2022;53(6):1892–903.CrossRefPubMed
4.
go back to reference Pandya KA, et al. Serotonin release assay (SRA)-negative HIT, a newly recognized entity: implications for diagnosis and management. Thromb Res. 2018;172:169–71.CrossRefPubMed Pandya KA, et al. Serotonin release assay (SRA)-negative HIT, a newly recognized entity: implications for diagnosis and management. Thromb Res. 2018;172:169–71.CrossRefPubMed
5.
go back to reference Warkentin TE, et al. Serotonin-release assay-negative heparin-induced thrombocytopenia. Am J Hematol. 2020;95(1):38–47.CrossRefPubMed Warkentin TE, et al. Serotonin-release assay-negative heparin-induced thrombocytopenia. Am J Hematol. 2020;95(1):38–47.CrossRefPubMed
6.
go back to reference Warkentin TE, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163(20):2518–24.CrossRefPubMed Warkentin TE, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163(20):2518–24.CrossRefPubMed
Metadata
Title
Cerebral venous sinus thrombosis associated with SRA-negative heparin-induced thrombocytopenia: case report
Authors
Floyd D. Silva
Allison E. Burnett
Anand Padmanabhan
Marian A. Rollins-Raval
Noah P. Splinter
Masoom J. Desai
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2023
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-023-00490-7

Other articles of this Issue 1/2023

Thrombosis Journal 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine